Trial · NCT02879162
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
NCT02879162, Phase 2, Completed, Canadian Cancer Trials Group; results first posted 2025-02-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours. Trials, record NCT02879162. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02879162
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
- NCT number
- NCT02879162
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 140 participants, actual
- Lead sponsor
- Canadian Cancer Trials Group
- Conditions
- Advanced Rare Tumours
- Interventions
- Durvalumab, Tremelimumab
- First posted
- 2016-08-25
- Last updated
- 2025-03-07
- Results first posted
- 2025-02-17
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate Measured by RECIST Version 1.1 | 48 months | Objective response rate is defined as the proportion of response evaluable patients who had complete response (CR) or partial response (PR) as their best response as assessed by RECIST version 1.1 criteria (i.e. a 30% decrease in the sum of the longest diameters of the target lesions maintained for at least 4 weeks (CR), or complete disappearance of disease and cancer related symptoms, also maintained for at least 4 weeks (CR)). |
| Secondary | Time to Progression Based on Kaplan-Meier Method | 48 months | defined as time from the date of randomization to the date of progression |
| Secondary | Progression Free Survival Based on Kaplan-Meier Method | 48 months | defined as time from the date of randomization to the date of progression or death |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate Measured by RECIST Version 1.1 | 48 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time to Progression Based on Kaplan-Meier Method | 48 months | months | MEDIAN | |
| SECONDARY | Progression Free Survival Based on Kaplan-Meier Method | 48 months | months | MEDIAN |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate Measured by RECIST Version 1.1 | Durvalumab + Tremelimumab | CR | 1 | Participants | |
| Objective Response Rate Measured by RECIST Version 1.1 | Durvalumab + Tremelimumab | PR | 19 | Participants | |
| Objective Response Rate Measured by RECIST Version 1.1 | Durvalumab + Tremelimumab | SD | 32 | Participants | |
| Objective Response Rate Measured by RECIST Version 1.1 | Durvalumab + Tremelimumab | PD | 76 | Participants | |
| Objective Response Rate Measured by RECIST Version 1.1 | Durvalumab + Tremelimumab | IN | 8 | Participants | |
| Time to Progression Based on Kaplan-Meier Method | Durvalumab + Tremelimumab | 2.8 | 95% Confidence Interval 2.6 to 2.9 | months | |
| Progression Free Survival Based on Kaplan-Meier Method | Durvalumab + Tremelimumab | 2.8 | 95% Confidence Interval 2.6 to 2.8 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Durvalumab + Tremelimumab | 140 | |
| Overall Study | COMPLETED | Durvalumab + Tremelimumab | 138 | |
| Overall Study | NOT COMPLETED | Durvalumab + Tremelimumab | 2 |
Source ClinicalTrials.gov
Adverse events302
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Durvalumab + Tremelimumab | 109 | 138 | |
| other | Diarrhea | Gastrointestinal disorders | Durvalumab + Tremelimumab | 64 | 138 | |
| other | Nausea | Gastrointestinal disorders | Durvalumab + Tremelimumab | 61 | 138 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Durvalumab + Tremelimumab | 61 | 138 | |
| other | Anorexia | Metabolism and nutrition disorders | Durvalumab + Tremelimumab | 59 | 138 | |
| other | Constipation | Gastrointestinal disorders | Durvalumab + Tremelimumab | 57 | 138 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Durvalumab + Tremelimumab | 53 | 138 | |
| other | Abdominal pain | Gastrointestinal disorders | Durvalumab + Tremelimumab | 47 | 138 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Durvalumab + Tremelimumab | 43 | 138 | |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Durvalumab + Tremelimumab | 42 | 138 |
1 to 10 of 302Source ClinicalTrials.gov
See all 302 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Durvalumab + Tremelimumab | 114 | 138 |
| Total, other adverse events | Durvalumab + Tremelimumab | 137 | 138 |
| Total, serious adverse events | Durvalumab + Tremelimumab | 80 | 138 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39737219 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02879162
GET https://conductscience.org/api/trials/v1/NCT02879162/events?page=2